PofoliaShared via Pofolia

PLoS Biology· 2026Q1

Collagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activation

Mona Nazemi, Bian Yanes, Eric Vancauwenberghe, Ifeoluwa Oyelade et al.

Short summary

Collagen I promotes breast and pancreatic cancer cell survival in nutrient-poor environments by activating the mTORC1 pathway, which increases amino acid import via the LAT1-4F2hc transporter.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Collagen I promotes cancer cell survival by enhancing amino acid import through the LAT1-4F2hc transporter.
  • This process activates mTORC1 signaling and S6 phosphorylation, crucial for cell growth.
  • Inhibiting α2β1 integrin or LAT1-4F2hc transporter significantly reduces cancer cell growth and invasion in 2D and 3D models.
  • LAT1-4F2hc expression is upregulated in basal-like breast and pancreatic cancers, correlating with poor prognosis and drug resistance.

AI-generated from the title and abstract; the full text is not read.

Abstract

Invasive breast and pancreatic cancer cells thrive within a collagen I-rich, poorly perfused extracellular matrix (ECM) network, necessitating robust metabolic adaptation to endure nutrient deficiency, such as glucose starvation. Here we demonstrate that collagen I is critical for the survival and growth of breast and pancreatic cancer cells. Mechanistically, collagen I promotes α2 β1 integrin-dependent S6 phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) and drives the membrane localisation of the (LAT1)−4F2hc amino acid transporter. This process ensures a sustained intracellular essential amino acid supply, further fuelling mTORC1 signalling and limiting autophagy. This collagen I-driven pathway is essential for cancer cell survival, as inhibiting the activity of α2 β1 integrin or the LAT1-4F2hc transporter significantly reduces cell growth and invasion in both 2D and 3D models. Finally, the clinical relevance of these transporters is underscored by the significant upregulation of LAT1-4F2hc expression in basal-like breast and pancreatic cancer patients, correlating with poor prognosis and drug resistance. Collectively, our findings highlight that targeting the LAT1−4F2hc transporter might represent a highly promising therapeutic strategy to limit cancer cell growth and invasion in highly fibrotic and nutrient-deprived tumours.

The authors' abstract, as published at the source. PLoS Biology, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Biochemistry (Biochemistry, Genetics and Molecular Biology)

BiochemistryBiochemistry, Genetics and Molecular Biology